CardioSignal has won the Kasvu Open award for the Growth Company of the Year. Kasvu Open, one of the biggest startup sparring and acceleration programs in Finland, chose the winners among 200 small and mid-sized companies.

CardioSignal, Inc. and JISEKI Health announced their upcoming collaboration. The companies plan to virtualize a care path for earlier detection of heart disease, starting from initial patient engagement, identifying at-risk individuals, and initiating remote patient monitoring. The goal is to improve early detection and health outcomes especially in vulnerable populations.

CardioSignal makes reliable heart disease detection available to smartphone users. An ambitious cybersecurity strategy is crucial to achieve accessibility and trust in new remote care models the company is developing with its customers globally.

With results that compare well with existing clinical methods, this study demonstrates the value of using motion sensor technology, available in most commercial smartphones today, for the detection of clinical heart failure. The multi-site study was conducted at three hospitals, including Stanford University Hospital, Turku University Hospital, and Helsinki University Hospital.

The study of >1000 patients reached its primary endpoint of recognizing clinical heart failure with smartphone-based technology. Comprehensive results of the study will be published later in 2022.

CardioSignal, a health technology company developing motion sensor technology to improve heart disease detection, was announced a winner in the Innovation Pitch Challenge by American College of Cardiology's Annual Scientific Session & Expo 2022 in Washington D.C. on April 3, 2022. The Pitch Challenge was organized in partnership with the National Heart Lung and Blood Institute (NHLBI).